nU-CAR-T19

nU-CAR-T19 is an allogeneic, gene-edited CAR-T cell therapy engineered to target CD19, primarily for the treatment of relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and other B-cell malignancies. This product is generated by using CRISPR/Cas9 editing to disrupt HLA-A, HLA-B, and TRAC (T cell receptor alpha constant) genes, which makes the CAR-T cells universal, resistant to host versus graft and natural killer (NK) cell-mediated rejection, and reduces risk of graft-versus-host disease (GvHD). nU-CAR-T19 cells exhibit potent antitumor activity, robust in vivo expansion, and result in rapid eradication of CD19+ leukemic cells with observed complete remission and minimal residual disease negativity in clinical settings. The design aims to provide an "off-the-shelf" therapeutic modality, overcoming significant product availability and manufacturing barriers seen with autologous CAR-T cell therapies[1][2].